- Home
- URGN
URGN
UroGen Pharma Ltd.
as 12-17-2024 4:00pm EST
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | RA'ANANA |
| Market Cap: | 547.1M | IPO Year: | 2017 |
| Target Price: | $44.50 | AVG Volume (30 days): | 351.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.08 | EPS Growth: | N/A |
| 52 Week Low/High: | $10.60 - $20.70 | Next Earning Date: | 11-06-2024 |
| Revenue: | $89,363,000 | Revenue Growth: | 15.64% |
| Revenue Growth (this year): | 13.39% | Revenue Growth (next year): | 45.06% |
Latest UroGen Pharma Ltd. News
URGN Breaking Stock News: Dive into URGN Ticker-Specific Updates for Smart Investing
Business Wire
12 days ago
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire
12 days ago
Long-Term Follow-up Study to the OLYMPUS Trial Presented at SUO 2024 Reports Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®
Business Wire
12 days ago
UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBC
Zacks
15 days ago
Wall Street Analysts Believe Urogen Pharma (URGN) Could Rally 209.92%: Here's is How to Trade
Business Wire
16 days ago
UroGen Announces New Data Presentations at the Society of Urologic Oncology 2024 Annual Meeting Highlighting Urothelial Cancer Portfolio Aimed at Addressing Unmet Needs
Clinical Trials Arena
20 days ago
UroGen reports long-term data from study of JELMYTO for LG-UTUC treatment
MT Newswires
22 days ago
UroGen Pharma Says Jelmyto Chemoablation Shows Long-Term Duration of Response in Urothelial Cancer Patients
Business Wire
22 days ago
New Data from a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®
Compare URGN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "URGN UroGen Pharma Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.